Entecavir and Lamivudine in patients with HBeAg-negative chronic hepatitis B patients with or without cirrhosis; incidence of Hepatocellular carcinoma.

Trial Profile

Entecavir and Lamivudine in patients with HBeAg-negative chronic hepatitis B patients with or without cirrhosis; incidence of Hepatocellular carcinoma.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Oct 2015

At a glance

  • Drugs Entecavir (Primary) ; Lamivudine
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Oct 2015 Results published in the Journal of Viral Hepatitis 22:120-7, No.2, 2015-02-01
    • 28 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top